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Hepatocellular carcinomas (HCC) are a major 
cause of cancer death and mostly develop as a 
result  of  advanced  liver  fibrosis.  Studies  have 
linked the development of HCC with a methyl-
ation-induced silencing of SOCS (suppressor of 
cytokine signaling) genes, which in turn leads to 
elevated activation of signal transducer and activa-
tor of transcription (STAT) 3 (1) or mutations of 
Axin1, a negative regulator of Wnt signaling (2). 
However, the mechanisms by which liver fibro-
sis induces cancer remain elusive.
It is well known that TGF- is an important 
cytokine in these fibrotic processes (3, 4) and that 
excess TGF- production is a key problem for 
the treatment of liver diseases as it triggers liver 
fibrosis (4). Three different gene products, TGF-
1, -2, and -3, have been cloned from mam-
malian tissues (5, 6) and mature TGF- proteins 
are composed of two 12.5-kD polypeptides. 
They are derived from 55-kD polypeptides, 
which dimerize upon synthesis followed by 
processing and secretion (7). Most studies describ-
ing biological effects of TGF- have examined 
how it affects targeted cells. In this paper, we have 
focused on intracellular processing of the TGF- 
complex before secretion. Transformation of he-
patocytes, but not of hepatic stellate cells (HSC) 
or Kupffer cells (KC), leads to cancer as a result 
of liver fibrosis. Although hepatocytes have not 
been considered a source of TGF-, we can hy-
pothesize that intracellular synthesis and modifi-
cation of TGF- in these cells is involved in 
cancer development.
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The molecular mechanisms underlying the development of hepatocellular carcinoma are not 
fully understood. Liver-specific signal transducer and activator of transcription (STAT) 5A/
B–null mice (STAT5-LKO) were treated with carbon tetrachloride (CCl4), and histological 
analyses revealed liver fibrosis and tumors. Transforming growth factor (TGF)– levels and 
STAT3 activity were elevated in liver tissue from STAT5-LKO mice upon CCl4 treatment. To 
define the molecular link between STAT5 silencing and TGF- up-regulation, as well as 
STAT3 activation, we examined STAT5-null mouse embryonic fibroblasts and primary hepa-
tocytes. These cells displayed elevated TGF- protein levels, whereas messenger RNA levels 
remained almost unchanged. Protease inhibitor studies revealed that STAT5 deficiency 
enhanced the stability of mature TGF-. Immunoprecipitation and immunohistochemistry 
analyses demonstrated that STAT5, through its N-terminal sequences, could bind to TGF- 
and that retroviral-mediated overexpression of STAT5 decreased TGF- levels. To confirm 
the in vivo significance of the N-terminal domain of STAT5, we treated mice that expressed 
STAT5 lacking the N terminus (STAT5-N) with CCl4. STAT5-N mice developed CCl4-
induced liver fibrosis but no tumors. In conclusion, loss of STAT5 results in elevated TGF- 
levels and enhanced growth hormone–induced STAT3 activity. We propose that a deregu-
lated STAT5–TGF-–STAT3 network contributes to the development of chronic liver disease.
This article is distributed under the terms of an Attribution–Noncommercial–
Share Alike–No Mirror Sites license for the first six months after the publication 
date (see http://www.jem.org/misc/terms.shtml). After six months it is available 
under a Creative Commons License (Attribution–Noncommercial–Share Alike 
3.0  Unported  license,  as  described  at  http://creativecommons.org/licenses/ 
by-nc-sa/3.0/).
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Liver fibrosis is reported to associate with acquired growth 
hormone (GH) resistance because of low GH receptor levels 
(22, 23). Although strong activation of STAT5 was observed 
in hepatocytes of control mice upon stimulation with GH, 
reduced activation was detected after CCl4 treatment (Fig. 1 E), 
suggesting that these cells loose their hormonal response dur-
ing early stages of fibrosis. STAT5 levels and activation were 
greatly reduced in STAT5-LKO mice before and after GH 
stimulation irrespective of CCl4 treatment. GH receptor lev-
els were largely independent of GH and CCl4 treatment.
We have recently reported that in the absence of STAT5, 
other STAT members, especially STAT3 and STAT1, could 
be recruited to receptors normally engaged by STAT5, which 
in turn would result in their aberrant activation (24, 25). As 
shown in Fig. 1 E, GH weakly induced tyrosine phosphory-
lation of STAT3 (pSTAT3) in control mice, which was exac-
erbated in the combined presence of GH and CCl4. In 
STAT5-LKO mice, strong STAT3 activation was observed 
even before GH injection and was even more pronounced upon 
GH treatment. Combined CCl4 and GH treatment further en-
hanced STAT3 activation in STAT5-LKO mice (Fig. 1 E). 
STAT3 levels were similar in the different groups. Expression 
levels of the STAT3 target genes fibrinogen  and haptoglobin 
were also increased in liver tissue from STAT5-LKO mice and 
further elevated upon GH and CCl4 treatment (Fig. 1 F and 
Fig. S3). STAT1 activation was largely independent of CCl4 
treatment (unpublished data). These results demonstrate that 
in the absence of STAT5, GH can directly activate STAT3, 
and that this activation is strongly enhanced by CCl4.
Development of liver cancer in STAT5-LKO mice
4 out of 20 STAT5-LKO mice had developed multiple tumors 
after 8 wk of CCl4 treatment, whereas none were detected in 
26 control mice (P = 0.0199; Fig. 2 A). Histological analysis re-
vealed that these tumors were mostly formed by moderately 
differentiated HCCs (Fig. 2 B). It has been established that most 
HCCs develop as a result of severe liver fibrosis. However, be-
cause STAT5-LKO mice had not developed severe fibrosis, we 
speculated these HCCs were induced through a different 
mechanism. We again confirmed an almost complete absence 
of nuclear STAT5B in STAT5-LKO mice, whereas it was 
present in hepatocytes from control mice (Fig. 2 C). Although 
little nuclear pSTAT3 was detected in control mice, STAT5-
LKO mice exhibited slightly stronger staining of pSTAT3 in 
nontumor tissue and extensive staining in tumor tissue (Fig. 2 D). 
These results indicate that STAT3 is gradually activated in the 
fibrosis-cancer process in STAT5-LKO mice.
TGF- protein levels, but not messenger RNA (mRNA) 
levels, are elevated in STAT5-null mouse embryo fibroblasts 
and primary hepatocytes.
To define the molecular link between STAT5 silencing, STAT3 
activation, and elevated TGF- levels, we performed experi-
ments with mouse embryonic fibroblasts (MEFs) from control 
and STAT5-null mice. We first confirmed the absence of STAT5 
expression and activation in cell lysates from STAT5-null MEFs 
The transcription factors STAT5 and STAT3 promote cell 
cycle progression and suppress apoptosis, thus contributing to cel-
lular transformation. Notably, activated STAT3 can mediate cel-
lular transformation (8) and has been detected in primary tumors 
including HCC (1, 9–11). Although STAT5 has been linked to 
tumorigenesis (12–15), it can also act as a tumor suppressor by in-
hibiting expression of NPM1-ALK (16). As for solid tumors, the 
role for STAT5 is controversial (17–19). To explore the role of 
cytokine signaling through STAT5 in liver fibrosis and cancer, 
we deleted the Stat5 locus specifically in hepatocytes using Cre-
mediated recombination. Using this experimental approach, we 
discovered a relationship between STAT5, TGF-, and STAT3 
in the pathogenesis of chronic liver disease.
RESULTS
Progression of liver fibrosis in hepatocyte-specific  
STAT5-null mice
Treatment of mice with carbon tetrachloride (CCl4) induces 
liver fibrosis and is an accepted model to mimic human disease. 
To examine the significance of cytokine-STAT5 signaling in 
the development of liver fibrosis, control mice and mice from 
which the Stat5 locus had been deleted in hepatocytes using 
Cre-mediated recombination (STAT5-LKO) were treated for 
8 wk with CCl4. Loss of STAT5 did not affect the sensitivity 
of primary hepatocytes to CCl4 and the slight increase of cell 
death was not significant (Fig. S1, A and B). Before treatment, 
there were no histological differences between mice from both 
groups based on silver and Azan staining (Fig. 1, A and B, top). 
The reticular fibers (Fig. 1, A and B, arrows) extended and de-
veloped into the interlobular septum in STAT5-LKO mice, 
whereas few reticular fibers deposited in the periportal tissue 
space in controls (Fig. 1 A, bottom). To evaluate fibrotic 
changes, we also performed Azan staining to detect collagen 
accumulation and identified the formation of nodules (Fig. 1 B, 
arrows) in STAT5 mutant mice (Fig. 1 B, bottom). In agree-
ment with these observations, the content of hepatic collagen 
was higher in STAT5-LKO mice after treatment (Fig. 1 C). 
These histological analyses and hepatic collagen assays revealed 
that STAT5 mutant mice displayed more advanced liver fibro-
sis than control mice.
TGF- levels and STAT3 activity are elevated in STAT5-LKO 
mice after CCl4 treatment
The deletion of the Stat5a/b locus in hepatocytes was con-
firmed by Western blot analyses and STAT5A/B levels were 
reduced by 80% (Fig. 1 D). TGF- (mature TGF-) levels 
were more profoundly induced in STAT5-LKO mice after 
CCl4  treatment  compared  with  controls.  Latent  TGF- 
binding protein (LTBP) levels were reduced in STAT5-LKO 
mice after CCl4 treatment and to a lesser extent in controls. 
This reduction of LTBP might be the result of an increased 
secretion of mature TGF- (20, 21). The expression levels of 
other  fibrogenesis-related  factors,  such  as  platelet-derived 
growth factor / and TGF- pseudo receptor Bambi, were 
examined and no differences were observed between control 
and STAT5-LKO mice (Fig. S2).JEM VOL. 206, April 13, 2009 
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Figure 1.  Progression of liver fibrosis in hepatocyte-specific Stat5A/B KO mice. (A and B) Silver staining (A) and Azan staining (B) of 
liver sections from STAT5A/Bf/f (control) mice and STAT5A/Bf/f;Alb-Cre (STAT5-LKO) mice before and after CCl4 treatment for 8 wk. Arrows indicate 
reticular fibers. All pictures are shown in low magnification (100×). Bars, 200 µm. (C) Quantification of total acid pepsin-soluble collagens in 
liver tissue of STAT5A/Bf/f and STAT5A/Bf/f;Alb-Cre before and after CCl4 treatment. Data are mean ± SD. The asterisk indicates a significant differ-
ence (P = 0.023) between the control and KO mice (n = 5–7). (D) Expression levels of STAT5A, STAT5B, TGF-, and LTBP in liver from control and 
KO mice before and after the treatment as detected by Western blot analysis. (E) Activation levels of STAT5 and STAT3 and expression levels of 
STAT5, STAT3, and GH receptor (GHR) in liver from control and KO mice before and after CCl4 treatment with or without GH stimulation as de-
tected by Western blot analysis. (F) Expression levels of fibrinogen  and Haptoglobin in liver from control and STAT5-LKO mice before and after 
CCl4 treatment with or without GH stimulation as detected by real-time RT-PCR analysis. The relative expression level of the untreated sample of 
control mice was set as 1, and the fold expression level of each sample was calculated (n = 3 in each group). Data are mean ± SD. Three inde-
pendent experiments were performed in triplicate and representative data were shown.822 ROLE OF STAT5 IN LIVER FIBROSIS | Hosui et al.
to be stimulated by autocrine and paracrine pathways (26). Based 
on  our  experiments  with  hepatocytes,  we  hypothesized  that 
TGF- levels would be elevated in STAT5-null MEFs, which 
by Western blot analyses (Fig. 3 A). Proliferation of control 
and STAT5-null MEFs was similar both in 15 and 3% FCS 
(Fig. 3 B). Fibroblastic cells are known to produce TGF- and 
Figure 2.  Development of cancer in hepatocyte-specific STAT5A/B KO mice. (A) Appearance of a representative hepatic tumor from STAT5A/ 
Bf/f;Alb-Cre mice after CCl4 treatment. Bar, 1 cm. (B) H&E staining of nontumor (left) and tumor (right) sections from STAT5A/Bf/f;Alb-Cre after CCl4 treatment. 
Bars, 40 µm. (C) Livers from STAT5f/f (left) and STAT5f/f;Alb-Cre (right) mice were harvested 30 min after GH injection and analyzed for STAT5B expression 
using by immunofluorescent staining with anti-STAT5B (red) and anti–-catenin (green) antibodies. Bars, 40 µm. (D) Tissues from STAT5f/f (top) and 
STAT5A/Bf/f;Alb-Cre (nontumor, top right; tumor, bottom) after CCl4 treatment are analyzed for pSTAT3 activation using immunofluorescent staining with 
anti-pSTAT3 (red) and anti–-catenin (green) antibodies. Strong activation of pSTAT3 is detected around the arrow. Bars, 40 µm.JEM VOL. 206, April 13, 2009 
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would lead to a paracrine activation and excess production of 
extracellular matrix protein. The intracellular content of col-
lagen was similar in MEFs from STAT5-null and control 
mice immediately after their preparation (Fig. 3 C, left). In 
contrast, elevated collagen levels were observed in STAT5-
null but not control MEFs after 10 passages. Similarly, colla-
gen levels were higher in culture medium obtained from 
STAT5-null MEFs after 1 mo in culture (Fig. 3 C, right). 
Furthermore, collagen levels were reduced in MEFs of the 
10th passage in the presence of anti–TGF- antibody, sug-
gesting that increased levels of TGF- caused excess produc-
tion of collagen. TGF- levels were greatly elevated in cell 
lysates and medium of STAT5-null MEFs compared with 
control MEFs (Fig. 3 D, top; and Fig. S4 ). GH-induced 
STAT3 activation was also elevated in STAT5-KO MEFs 
(Fig. 3 D, bottom), which is similar to what was observed in 
liver section from treated mice. Increased TGF- levels and 
GH-induced STAT3 activation were also observed in pri-
mary hepatocytes stimulated by CCl4 (Fig. S5).
To confirm that excessive collagen production was linked 
to an increase of TGF-, protein and mRNA levels in cell 
lysates were examined. Mature TGF- levels were 20-fold 
elevated in STAT5-null MEFs, and these differences were 
independent of IL-6 or TGF- stimulation (Fig. 3 E). How-
ever, mRNA levels for TGF- were similar in both cells ir-
respective of IL-6 or TGF- stimulation (Fig. 3 F).
Loss of STAT5 enhances the stability of mature TGF-
Because TGF- mRNA levels were similar in control and 
STAT5-null MEFs, we examined the effects of STAT5 on 
TGF- protein stability and monitored TGF- levels after in-
hibiting protein synthesis with cycloheximide (CHx). Serum-
starved wild-type and STAT5-null MEFs were treated with 
CHx for 0-6 h, harvested, and protein was extracted. Although 
the levels of mature TGF- remained fairly stable in STAT5-
null cells, they rapidly declined in control cells. Quantitative 
analysis confirmed an elevated half-life of mature TGF- in 
STAT5-null MEFs (Fig. 3 G). To understand the underlying 
mechanism, we tested the effects of the lysosomal inhibitor 
ammonium chloride on the loss of mature TGF-. Pretreat-
ment with this inhibitor restored the levels of mature TGF- 
in wild-type MEFs in the presence and absence of CHx, whereas 
it did not change levels in STAT5-null MEFs (Fig. 3 H). These 
results demonstrate that loss of STAT5 enhances the stability 
of mature TGF- protein.
Interaction of the STAT5 N terminus with TGF-
We next used a combination of immunoprecipitation (IP) 
and immunoblotting to explore the possibility of a physical 
interaction between STAT5 and TGF- (Fig. 4, A and B). 
Cell lysates from STAT5-null and control MEFs, as well as a 
mixture of the two lysates, were applied to IP followed by 
immunoblotting. TGF- was found to interact with STAT5A 
in extracts from wild-type cells (Fig. 4 A, top). STAT5-null 
cells served as a negative control. Binding of TGF- to 
STAT5B was detected in mixed lysates (Fig. 4 A, bottom). 
To confirm the interaction between TGF- and STAT5, we 
performed the reverse assay performing the IP with antibody 
against TGF- (Fig. 4 B). Again, binding of STAT5A and 
STAT5B to TGF- was established.
Mature TGF- binds to LTBP, forming latent TGF-, 
which is subsequently secreted. We examined which part of 
the TGF- complex binds to STAT5 (Fig. 4 C). STAT5A/B 
were not detected in immunoprecipitates using LTBP anti-
bodies and LTBP was also not identified in immunoprecipi-
tates using STAT5A/B antibodies. TGF- was found to bind 
to STAT5A/B but not to LTBP. Furthermore, these results 
indicate that the TGF- complex is not detected inside cells 
after it binds to LTBP, whereas TGF- is present in the cy-
toplasm after it binds to STAT5A/B.
To determine whether known functional amino acids in 
STAT5 are required for the interaction with TGF-, we gen-
erated retroviral vectors encoding wild-type or mutant STAT5. 
First we prepared retroviruses carrying the wild-type STAT5a 
gene as well as mutations in amino acids, which are crucial for 
the function of STAT5A (27–29). None of these mutations ad-
versely affected the interaction between STAT5A and TGF-, 
and their presence led to the suppression of TGF- levels in 
STAT5-null MEFs, whereas mRNA levels for TGF- were 
similar in these cells (Fig. 4 D and Fig. S6).
To further determine which region of STAT5 interacts with 
TGF-, we generated expression vectors carrying either wild-
type STAT5 (pWild-T7) or various deletion mutants (pC1-
T7, pC2-T7, pN1-T7, and pN2-T7; Fig. 4 E). Using an 
in vitro transcription–translation system with l-[35S]methionine, 
similar levels of wild-type and mutant STAT5A proteins were 
synthesized (Fig. 4 F). Subsequently, these STAT5 proteins were 
incubated with cellular lysates from STAT5-null MEFs and   
immunoprecipitated with antibody against TGF- (Fig. 4 G). 
STAT5AC1 and C2, as well as wild-type STAT5A, were 
detected after SDS-PAGE fractionation, whereas STAT5AN1 
and N2 did not bind to TGF-. We conclude that the 94   
N-terminal amino acids of STAT5 are critical for the interaction 
with TGF-.
Because STAT1 and STAT3 share similarities with STAT5 
(30), we asked whether their N termini were also able to inter-
act with TGF-. Using in vitro expression vectors encoding 
the N-terminal domains of STAT5A/B, STAT3, and STAT1 
we determined that the N-terminal domains of STAT5A/B, 
but not those of STAT3 and STAT1, interacted with TGF- 
(Fig. 4, H–J).
To determine the intracellular localization of each protein, 
we generated vectors expressing TGF- with a V5 tag and 
STAT5A coexpressing GFP. STAT5-null MEFs were infected 
with  the  STAT5A-expressing  retrovirus  and  subsequently 
transfected with the TGF-–V5 plasmid. GFP, an indicator of 
STAT5A expression, was found preferentially in the nucleus 
but also in the cytoplasm (Fig. 4 K, top right). In contrast, 
TGF- was detected preferentially in the cytoplasm (Fig. 4 K, 
top left). Cytoplasmic colocalization of STAT5A and TGF- 
was observed (Fig. 4 K, bottom right).824 ROLE OF STAT5 IN LIVER FIBROSIS | Hosui et al.
Figure 3.  TGF- protein levels are enhanced in STAT5A/B-null MEFs. (A) Changes in the pSTAT5 and STAT5B levels in control and STAT5-null MEFs 
before and after GH stimulation as detected by Western blot analysis. (B) Control and STAT5-null MEFs were seeded on a 96-well culture plate, main-
tained in 15% FCS (left) or 3% FCS (right), and viable cells were assessed by the WST colorimetric assay. Data are mean ± SD. (C) Quantification of total 
collagen in cell lysates of MEFs (left) or in culture medium (right). Primary MEFs (bars 1 and 4) or MEFs after 10 passages in the absence (bars 2 and 5) or 
presence (bars 3 and 6) of TGF- antibody were used. Neutralization antibody was added to the medium every passage (final concentration, 100 ng/ml). JEM VOL. 206, April 13, 2009 
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Data are mean ± SD. The asterisks indicate significant differences (left, P = 0.024 [left] or P = 0.011 [right]; right, P = 0.021 [left] or P = 0.024 [right]).  
(D) Changes in TGF- levels and STAT3 activation in primary MEFs and MEFs after 10 passages before and after GH stimulation as detected by Western 
blot analysis. (E) Changes in TGF- levels of cell lysates in control and STAT5-null MEFs before and after TGF- or IL-6 stimulation as detected by Western 
blot analysis. (F) Expression levels of TGF-1, 2, and 3 mRNA in both cells before and after stimulation as detected by real-time RT-PCR analysis. The 
relative expression level of untreated sample of control MEFs was considered as 1, and the fold expression level of each sample was calculated. Data are 
mean ± SD. (G and H) Changes in TGF- levels in control (two lines were used) and STAT5-null MEFs before and after CHx or ammonium chloride treat-
ment. The intensity of protein bands was measured by AlphaImager (Alpha Innotech). The relative intensity level of the untreated sample of each MEF was 
considered as 1, and the intensity level of each sample was calculated. Three independent experiments were performed and representative data are 
shown. Recombinant murine TGF- protein (Wako Chemicals USA, Inc.) was used as a positive control (H, right).
TGF- levels are controlled by STAT5
We have demonstrated an interaction between STAT5 and 
TGF- and that elevated TGF- levels in STAT5-null cells are 
a result of an enhanced stability. To further establish a causal re-
lationship between STAT5 and TGF- levels, we expressed 
wild-type STAT5 and different mutants in STAT5-null MEFs 
and analyzed TGF- levels. The efficiency of retroviral infec-
tion was equivalent for all constructs (Fig. 4 L). GFP-positive 
cells were isolated, and subjected to Western blot analysis. 
TGF- levels were elevated in STAT5-null MEFs compared 
with wild-type cells. Infection with retroviruses expressing wild-
type, C1, and C2 STAT5A decreased TGF- to almost un-
detectable levels. In contrast, TGF- levels remained unaltered 
upon expression of STAT5N1 and N2 (Fig. 4 M).
To address the question of whether the interaction with 
STAT5 would prevent TGF- from shuttling to lysosomes, we 
purified lysosomes and analyzed the presence of STAT5-TGF- 
complexes. This complex was present in lysosomes in a STAT5A 
dose-dependent manner (Fig. S7), suggesting that binding to 
STAT5 does not prevent TGF- shuttling to lysosomes.
GH-induced STAT3 and STAT5 activation is modulated  
by TGF-
To explore the physiological consequences of the STAT5–
TGF- interactions on STAT5 activity, we infected control 
MEFs with a retrovirus expressing TGF-/GFP. After treat-
ment with or without GH, GFP-positive cells were isolated 
and protein extracts were analyzed. Phosphorylated STAT5 
was detected upon GH stimulation in the absence of exoge-
nous TGF- but not in its presence (Fig. 5). Intriguingly, 
strong GH-induced STAT3 activation was detected only in 
the presence of exogenous TGF-. The levels of STAT5A/B, 
STAT3, and GH receptor were equivalent before and after 
GH stimulation irrespective of TGF- expression. These find-
ings demonstrate that TGF- levels determine whether GH 
activates STAT3 or STAT5.
The STAT5 N terminus is critical for the development  
of liver fibrosis
To further explore the in vivo role of the STAT5 N-terminal 
domain in the process of liver fibrosis, we took advantage of 
mice that express an N-terminal truncated form of STAT5 (31). 
We generated mice that carry one allele encoding STAT5A/B 
lacking the first 90 amino acids, one Stat5 floxed allele, and the 
Alb-Cre transgene (STAT5fl/N;Alb-Cre mice). Western blot anal-
yses confirmed the presence of STAT5A/B-N in liver tissue 
(unpublished data). Control mice (STAT5fl/fl), STAT5fl/fl;Alb-Cre 
(STAT5-LKO), and STAT5fl/N;Alb-Cre (STAT5-N) mice 
were treated for 8 wk with CCl4. Hematoxylin-eosin (H&E) 
staining revealed an accumulation of fat droplets in STAT5-
LKO but not in control or STAT5-N mice (Fig. 6 A, top). 
Upon treatment with CCl4, we observed extended reticular fi-
bers that developed similarly in STAT5-N and STAT5-LKO 
mice but to a lesser extent in controls (Fig. 6 A, middle). Azan 
staining revealed the formation of nodules and collagen accu-
mulation in STAT5-N and STAT5-LKO mice (Fig. 6 A, 
bottom). In agreement with these histological findings, increased 
levels of hepatic collagen were detected after CCl4 treatment 
(unpublished data). However, no tumors were detected in 17 
STAT5-N mice. These results indicate that the STAT5 N 
terminus is dispensable for the tumor suppressor function of 
STAT5. Furthermore, it strongly suggests that fat accumulation 
in STAT5-LKO mice has almost no effect on the fibrotic pro-
cess because STAT5-N and STAT5-LKO mice had a similar 
degree of liver fibrosis after treatment.
DISCUSSION
GH resistance and low serum levels of insulin-like growth fac-
tor 1 have been identified in a large percentage of cirrhotic   
patients (23, 32), suggesting a link between STAT5 signaling and 
liver fibrosis and possibly HCC. In this paper, we have dem-
onstrated that TGF- directly interacts with STAT5 and that 
elevated levels of TGF- abrogate GH-induced STAT5 acti-
vation. Instead, elevated levels of TGF- result in GH activa-
tion of STAT3, and constitutive STAT3 activity is commonly 
observed in HCC. Elevated phosphorylation of STAT3 has 
been associated with epithelial cancers and linked to the in-
duction of STAT3 target genes. In support of a STAT5–TGF-
–STAT3 mechanism, deletion of STAT5 from hepatocytes 
in mice resulted in elevated levels of TGF-, an activation of 
STAT3, and, finally, the development of HCC. We hypothe-
size that a TGF-–mediated abrogation of STAT5 signaling 
results in the activation of STAT3, which is a key step in the 
development of HCC (Fig. 6 B).
Most likely, the development of liver cancer in this model is 
the result of more than one molecular insult. Notably, excessive 
STAT3 activation upon GH and CCl4 treatment in STAT5-
LKO mice could result in unscheduled cell proliferation and 
transformation. TGF- binds to the N terminus of STAT5, and 
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does not result in increased liver cancer induced by CCl4, its 
contribution to oncogenesis might be cell specific. Moriggl et al. 
(37) established that loss of the N-terminal region protected 
the development of certain leukemia. At this point, the cell 
specificity of STAT5 in normal development and oncogenesis 
is poorly understood.
TGF- and STAT3 are not only critical in the promotion of 
tumor progression and survival but they also contribute to tu-
mor-immune escape (38, 39). Notably, increased TGF- secre-
tion might lead to the expansion of CD4+CD25+FoxP3+ 
regulatory T (T reg) cells that would impact liver fibrosis and tu-
mor development (40, 41). Another possibility for the promo-
tion of liver fibrosis is that the deletion of STAT5 might have an 
effect on HSC or KC and increase their sensitivity to TGF-. 
However, the CD4/CD8 ratio and TH1- and TH2-cytokine 
production were similar in control and mutant mice (Fig. S8, 
A–C), and no selective expansion of T reg cells was observed   
after CCl4 treatment (Fig. S8, D and E). Moreover, the sensitivity 
of HSC to TGF- in isolated HSC was identical in both mice 
(Fig. S9). These results contributed to a nonbiased analysis of the 
role of STAT5 in liver fibrosis and cancer development.
In the absence of inflammation, liver TGF- is secreted 
from HSC and KC but not from hepatocytes. However, upon 
inflammation or injury hepatocytes gradually become the ma-
jor source of TGF- (42–45). As hepatic fibrosis develops, 
TGF- levels increase, followed by the accumulation of ex-
tracellular matrix (4). Collectively, hepatocytes secrete an ex-
cess of TGF- in the late stage of liver fibrosis when most 
cancer develops. It has been shown that TGF-1 induces an 
epithelial-to-mesenchymal transition in mature hepatocytes, 
resulting in type I collagen synthesis (46, 47). Because embry-
onic  fibroblasts  secrete  TGF-,  MEFs  are  reminiscent  of 
myofibroblasts,  which  are  activated  in  liver  fibrosis  state. 
TGF- levels were highly elevated in STAT5-null MEFs and 
reintroduction of STA5 resulted in the suppression of TGF-. 
Based on our studies, we propose that binding of STAT5 to 
TGF- reduces its half-life. STAT5 has been reported to in-
teract with other molecules, such as the glucocorticoid recep-
tor (GR) and HNF (hepatocytes nuclear factor) 4 (48, 49). 
Although the GR can act as a transcriptional coactivator of 
STAT5 and enhances STAT5-dependent transcription, the 
GR–STAT5 complex diminishes the glucocorticoid response 
loss of STAT5 led to elevated TGF- levels as a result of in-
creased stability. The absence of the STAT5 N terminus in 
STAT5-N mice did not abrogate the development of liver fi-
brosis, but no tumors were observed in these mice. This sug-
gests that an N-terminally truncated STAT5 still contains tumor 
suppressor functions similar to that seen with wild-type STAT5. 
Several studies that compared STAT5-N mice and mice com-
pletely missing STAT5A/B established functional activity of the 
N-terminally  truncated  STAT5.  For  example,  although  the 
complete loss of STAT5 results in perinatal lethality, STAT5-
N mice are viable (33). Similarly, the complete loss of STAT5 
causes more severe hematological defects (34, 35). A recent 
study demonstrated that the N-terminal domain plays an im-
portant role in maintaining normal balance of lymphoid and 
myeloid cells (36). Although it is clear that loss of STAT5 N 
terminus, which is required for the tetramerization of STAT5, 
Figure 4.  STAT5 binds to TGF- and controls its levels. (A and B) Cellular lysates from wild-type and/or STAT5-null MEFs were immunoprecipitated 
with nonspecific -globulin and antibodies against STAT5A/B or TGF-, and the immunoprecipitates were subjected to Western blotting. (C) Cellular  
lysates from STAT5 wild-type MEFs were immunoprecipitated with nonspecific -globulin and antibodies against LTBP or STAT5A/B. The immunoprecipi-
tates were subjected to Western blotting. (D) Expression levels of STAT5A and TGF- in wild-type MEFs, STAT5-null MEFs, and STAT5-null MEFs infected 
with various kinds of retroviral STAT5-expressing vector. After infection, GFP-negative/positive cells were sorted and applied to Western blot analysis.  
(E and H) Schematic presentation of protein-expressing plasmids. (F and I) Aliquots of in vitro translation products from each plasmid were fractionated 
by SDS-PAGE. The proteins were labeled with l-[35S]methionine. (G and J) In vitro–synthesized wild-type and mutant STAT5A and the N-terminal domain 
of each STAT protein were mixed with cellular lysates and immunoprecipitated with TGF- antibody. (K) STAT5-null MEFs were infected with STAT5A-GFP–
expressing retrovirus and transfected with pUB6–TGF-–V5, which expresses a TGF-–V5 fusion protein. Cells were analyzed for TGF- and STAT5A using 
immunofluorescent staining with anti-V5 (red) and anti-GFP (green) antibodies. Nuclei were stained with DAPI (blue). Bar, 10 µm. (L) Flow cytometry  
detection of STAT5-GFP–infected cells from STAT5 KO MEFs infected with various kinds of STAT5-expressing retrovirus. The ratio of GFP-positive cells is 
shown in each graph. (M) TGF- levels in wild-type, STAT5-null MEFs, and STAT5-null MEFs infected with different STAT5-expressing retroviruses. After 
infection, GFP-positive cells were sorted and subjected to Western blotting.
Figure 5.  GH-induced STAT3 and STAT5 activation is modulated by 
TGF-. Phosphorylation levels of STAT5 and STAT3 and expression levels of 
TGF-, STAT5A, STAT5B, STAT3, and GH receptor in STAT5 wild-type MEFs 
before and after GH stimulation were determined by Western blot analysis. 
STAT5 wild-type MEFs were infected with a retrovirus based on pMSCV–
TGF-–GFP vector, sorted, and applied to Western blot analysis.
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Figure 6.  The N-terminal domain of STAT5 is critical for the development of liver fibrosis. (A) H&E staining of liver sections from control, 
STAT5-LKO, and STAT5-N mice before CCl4 treatment (top) and silver (middle) and azan (bottom) staining of liver sections from these mice after CCl4 
treatment. Arrows indicate reticular fibers. H&E images are shown at high magnification (400×; bars, 50 µm), and others are at low magnification (100×; 
bars, 200 µm). n = 3–5 in each group. (B) Model for the development of liver fibrosis and cancer through elevated expression of TGF- and activation of 
STAT3 in hepatocytes. Under physiological conditions, TGF- is present at low or nondetectable levels and some is secreted after binding to LTBP in a 
constitutive fashion. STAT5 binds to TGF- and interferes with the formation of TGF- complex, resulting in suppression of TGF- protein stability. At this 
level of TGF-, STAT5 levels and activation are not influenced. Upon development of liver fibrosis, TGF- levels increase and LTBP levels decrease. Under 
these conditions, STAT5 is sequestered by TGF- and can no longer be activated by GH. Instead, GH activates STAT3.JEM VOL. 206, April 13, 2009 
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applied in this study. The detailed procedure is described elsewhere (54). In 
short, the cellular protein was extracted from control and STAT5/ MEFs 
and precleared by incubation with protein A–Sepharose beads at 4°C for 1 h. 
Next, the sample was incubated with the beads coupled to the TGF- or 
STAT5A/B antibody, or with the rabbit nonspecific -globulin (Dako) for 
18 h. The immune complex was eluted by being boiled for 5 min. Finally, the 
supernatant was used for Western blot to detect the TGF- or STAT5A/B. 
To confirm the binding site of STAT5A protein to TGF- protein, several 
STAT5A proteins possessing the wild-type or some deleted amino acid se-
quences were synthesized from pC1-T7, pC2-T7, pN1-T7, pN2-T7 
(indicated in Fig. 4 E), pS5AC, p5SBC, pS3C, and pS1C (indicated 
in Fig. 4 H) by the in vitro translation method. The reaction was performed 
with the TNT T7 coupled reticulocyte lysate system (Promega) and labeled 
with l-[35S]methionine (GE Healthcare). The cellular lysates from STAT5 
wild-type MEFs were extracted and mixed with various types of the in vi-
tro–synthesized STAT5A/B, STAT3, or STAT1 proteins. The mixture was 
then subjected to IP using antibody against TGF- as described in the first 
half of this paragraph. Finally, the immunoprecipitate was separated with 
SDS-PAGE and the gel was dried and autoradiographed.
Plasmid constructs. Retroviral-expressing vectors of wild-type STAT5A, 
partially deleted STAT5A, and TGF- were constructed from pMSCV-
IRES GFP new polylinker (provided by R. Moriggl, Ludwig Boltzmann 
Institute for Cancer Research, Vienna, Austria). First, pMSCV-STAT5A-
GFP or pMSCV–TGF-–GFP, carrying the entire STAT5a complementary 
DNA (cDNA) or TGF- cDNA, was made up by inserting each gene into 
EcoRI and SacII sites. Four kinds of single amino acid–mutated STAT5a 
expression vectors were generated by site-directed mutagenesis (T92A, from 
aca to gca; T97A, from acg to gcg; Y694F, from tac to ttc; and S725A, from 
tcc to gcc). Other retroviral-expressing vectors of partly deleted STAT5a, 
such as C1, C2, N1, and N2, were also made up by inserting each 
PCR product (indicated in Fig. 4 E). For the synthesis of entire or partly de-
leted STAT5 protein in vitro, we also made five kinds of expressing plas-
mids,  each  of  which  carries  the  entire  or  deleted  region  of  STAT5a 
downstream of the T7 promoter based on pET161/GW/D-TOPO (Invit-
rogen). To examine the intracellular localization of STAT5 and TGF- pro-
teins, we generated two expressing plasmids with a certain tag. One of them 
is pUB6-TGF--V5, which carries the entire TGF- gene attached with V5 
tag in the C terminus of TGF-, and the other is pMSCV-GFP-STAT5A, 
which has the STAT5a gene with GFP in the N terminus of STAT5a.
Collagen quantitation. Collagen concentration in liver was determined 
using the Sircol collagen assay (Biodye Science). In brief, 50 mg of liver tis-
sue was homogenized, and total acid pepsin-soluble collagens were extracted 
overnight using 5 mg/ml pepsin in 500 ml of 0.5 M of acetic acid. 1 ml of 
Sircol dye reagent was added to 100 µl of each sample in duplicate at 25°C 
for 30 min. After centrifugation, the pellet was suspended in 1 ml of alkali 
reagent, and absorbance was read at 540 nm.
Production and infection of retrovirus. For making retrovirus, 293T 
cells were transfected with various kinds of pMSCV-IRES-GFP and Ecopac 
(the  plasmid  containing  packaging  sequences,  pIK6.1MCV.ecopac.UTd)   
using FuGENE (Roche). All supernatants were collected for 48–72 h after 
transfection and passed through a 0.45-µm filter before freezing at 80°C.
For the infection of retrovirus to MEFs, 106 cells were seeded on a 10-cm 
culture dish and were infected the next day with retrovirus in the presence 
of 8 µg/ml polybrene. 48–72 h after infection, the cells were lysed and sub-
jected to the subsequent experiments.
FACS. After infection with retrovirus, MEFs were trypsinized, washed twice 
in PBS, resuspended in 1 ml of PBS, and, finally, subjected to flow cytometry 
(FACSCalibur; BD). Nonfluorescent cells and GFP-expressing cells were 
isolated using the FACS Vantage (BD) and sorted directly into PBS. Protein 
was extracted from each population and applied to Western blot analyses.
of promoters harboring glucocorticoid response elements. As 
for HNF-4, it strongly inhibits GH-induced STAT5B tran-
scriptional activity. Although STAT5 decreases TGF- stabil-
ity, resulting in a reduction of TGF-, excess levels of TGF- 
inhibit GH-induced activation of STAT5. In this context, 
GH preferentially activates STAT3, which in turn activates 
genes linked to cell proliferation and survival. Thus, STAT5 
transcriptional functionality can be modulated by activating 
and suppressing cofactors (50).
The unscheduled ability of STAT3 to be activated by   
cytokines that normally only activate STAT5 is no artifact of 
the STAT5-KO mouse model. Recently, several inactivating 
STAT5B mutations have been identified in humans (51, 52) 
and linked to dwarfism and immunological disorders. Stimu-
lation of primary cells from these patients with GH and pro-
lactin leads to an unscheduled activation of STAT3 (52), and 
it is conceivable that some of the immunological disorders 
observed in these patients can be linked to the aberrant ac-
tivation of STAT3 rather than the loss of STAT5B. With   
respect to liver fibrosis and HCC, we propose that TGF-– 
mediated down-regulation of STAT5 levels in hepatocytes 
leads to an aberrant activation of STAT3.
MATERIALS AND METHODS
Mice and treatment. Through breeding, we generated STAT5A/Bfl/fl;Alb-Cre, 
STAT5A/Bfl/fl, and STAT5A/Bfl/N;Alb-Cre mice, which are in a mixed 
background (STAT5-N mice were provided by J.N. Ihle, St Jude’s Chil-
dren’s Research Hospital, Memphis, TN) (30, 33, 53). Only 10–18-wk-old 
female mice were used in the experiment unless otherwise indicated. Prim-
ers for genotyping STAT5 were described elsewhere (33). Hepatic fibrosis in 
mice was induced by i.p. injection with 2 ml/kg body weight of 10% CCl4 
(Sigma-Aldrich) dissolved in olive oil (Sigma-Aldrich) three times a week for 
8 wk. As for GH stimulation, mice were injected with 2 µg/g body weight 
of GH i.p., and 30 min after injection they were sacrificed. We treated the 
animals humanely and performed procedures according to the protocol ap-
proved by the Animal Use and Care committee at the National Institute of 
Diabetes and Digestive and Kidney Diseases.
Isolation of MEF cells. MEFs were isolated from embryonic day–14 em-
bryos of wild-type and STAT5A/STAT5B/ mice by first mincing the 
embryos, digesting in 0.05% trypsin/0.02% EDTA for 30 min at 37°C, pellet-
ing the tissue, and resuspending in growth medium consisting of DMEM 
containing 10% FCS (31). MEFs were maintained in high-glucose DMEM 
supplemented with 15% FCS, 50 µg/ml streptomycin sulfate, 50 units/ml of 
penicillin G sodium, and nonessential amino acid in 5% CO2 at 37°C.
Antibodies, immunostaining, and immunoblotting. The rabbit poly-
clonal anti-STAT5A (L-20), anti-STAT5B (C-17), and anti-STAT3 (C-20) 
antibodies were purchased from Santa Cruz Biotechnology, Inc. The rabbit 
phospho-STAT5 (Tyr694), phospho-STAT3 (Tyr705), and TGF- anti-
bodies were obtained from Cell Signaling Technology. Mouse monoclonal 
-actin antibody was purchased from Millipore and Santa Cruz Biotechnol-
ogy, Inc. Anti-LTBP, anti-GH receptor, and anti–TGF- neutralization an-
tibodies were obtained from R&D Systems, and anti-GFP and anti-V5 
antibodies were obtained from Invitrogen. Immunohistochemistry and   
immunoblotting were performed using standard procedures according to the 
manufacturers’ instructions. Some blots are shown in larger areas (Fig. S10).
Protein–protein interaction analysis. To examine the binding of the 
STAT5  protein  to  TGF-  protein,  the  IP/Western  blot  analyses  were   830 ROLE OF STAT5 IN LIVER FIBROSIS | Hosui et al.
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Histology. H&E, silver staining, and Azan staining were performed using stan-
dard procedures. In short, liver pieces were rapidly removed and fixed in 10% 
neutral buffered formalin, processed routinely, and embedded in paraffin wax. 
The sections were cut to appropriate thickness followed by each staining.
RNA extraction and real-time PCR analysis. Total RNA was isolated 
(RNeasy mini kit; QIAGEN ), and then 1-µg amounts of RNA were re-
verse transcribed (SuperScript III First-Strand Synthesis SuperMix; Invitro-
gen), and cDNAs were amplified using Taqman (for fibrinogen  and 
haptoglobin) or SYBR Green master mix and probe (for TGF-1, 2, and 3; 
Applied Biosystems). These assays were performed according to the manu-
facturers’ instructions.
Analysis of cell growth. To examine the cell growth curve, 5 × 103 wild-
type and STAT5 KO MEFs were seeded on a 96-well culture plate. After 3, 
6, and 9 d, the net number of viable cells was assessed colorimetrically using 
water-soluble tetrazolium (WST; 2-[2-methoxy-4-nitrophenyl]-3-[4-nitro-
phenyl]-5-[2, 4-disulfophenyl]-2H-tetrazolium monosodium salt; Roche). 
This assay is based on the cleavage of tetrazolium salt by mitochondrial de-
hydrogenase in viable cells. For the assay, 10 µl WST reagent was added to 
the 100-µl culture medium, followed by incubation at 37°C for 2 h. Then 
the optical density at 450 nm was measured. The assay was done in quadru-
plicate, and the values were expressed as the means ± SD.
Degradation of TGF- after blockade of protein synthesis and ef-
fects of lysosome inhibitors on TGF- stability. STAT5 wild-type 
(two independent lines) and KO MEFs were grown to 80% confluence in 
60-mm dishes and serum starved overnight. Cells were then incubated with 
20 mg/ml CHx for 0–6 h or 100 mM ammonium chloride for 2 h followed 
by CHx or PBS treatment. Cells lysates were resolved by SDS-PAGE and 
blotted with anti–TGF- antibody.
Statistics. All statistical analyses were performed using a two-tailed unpaired 
Student’s t test. A p-value of 0.05 or less was considered significant.
Online supplemental material. Fig. S1 shows cell availability in isolated 
hepatocytes and the ratio of apoptotic cells in liver tissues. Fig. S2 shows ex-
pression levels of fibrosis-related gene in liver tissues. Fig. S3 shows expres-
sion levels of fibrinogen . Fig. S4 shows serum TGF- levels in MEF 
culture medium. Fig. S5 shows pSTAT3 and TGF- levels in isolated hepa-
tocytes before and after CCl4 treatment. Fig. S6 shows TGF-1 expression 
levels in various kinds of MEFs. Fig. S7 shows the existence of the TGF-–
STAT5 complex in lysosome fraction. Fig. S8 shows the immunological 
analysis, CD4/CD8 ratios, B cell ratios, cytokine production, and T reg cell 
ratios. Fig. S9 shows pSMAD2 level in isolated HSCs. Fig. S10 shows a 
larger area of some Western blots. Online supplemental material is available 
at http://www.jem.org/cgi/content/full/jem.20080003/DC1.
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